CD20-directed Cytolytic Antibody [EPC]

146956 reported adverse events

Drugs of this class: OFATUMUMAB OBINUTUZUMAB OCRELIZUMAB RITUXIMAB RITUXIMAB AND HYALURONIDASE RITUXIMAB-ABBS RITUXIMAB-ARRX RITUXIMAB-PVVR

These side effects are most commonly reported by patients taking drugs of the CD20-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 20518
1 OFF LABEL USE 13185
2 FATIGUE 11198
3 RHEUMATOID ARTHRITIS 11018
4 PAIN 9612
5 NAUSEA 7006
6 PYREXIA 6913
7 INFUSION RELATED REACTION 6565
8 PNEUMONIA 6563
9 RASH 6529
See all common reactions for CD20-directed Cytolytic Antibody [EPC]

Drugs of the CD20-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 1311 0.7365
1 RED BLOOD CELL SEDIMENTATION RATE 118 0.7108
2 SWOLLEN JOINT COUNT INCREASED 223 0.6925
3 CHRONIC LYMPHOCYTIC LEUKAEMIA RECURRENT 303 0.6918
4 PEMPHIGUS 3165 0.6770
5 B-CELL LYMPHOMA RECURRENT 258 0.6386
6 MANTLE CELL LYMPHOMA RECURRENT 122 0.6256
7 GRANULOMA SKIN 316 0.5788
8 RHEUMATOID FACTOR POSITIVE 1213 0.5652
9 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 193 0.5643
See all enriched reactions for CD20-directed Cytolytic Antibody [EPC]